Nizatidine (BioDeep_00000002917)

   

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


dimethyl[(4-{[(2-{[(E)-1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}-1,3-thiazol-2-yl)methyl]amine

化学式: C12H21N5O2S2 (331.1137)
中文名称: 尼扎替丁
谱图信息: 最多检出来源 Mentha canadensis(plant) 51.61%

分子结构信息

SMILES: CN/C(=C\[N+](=O)[O-])/NCCSCc1csc(CN(C)C)n1
InChI: InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3

描述信息

Nizatidine is only found in individuals that have used or taken this drug. It is a histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. [PubChem]Nizatidine competes with histamine for binding at the H2-receptors on the gastric basolateral membrane of parietal cells. Competitive inhibition results in reduction of basal and nocturnal gastric acid secretions. The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin.
A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BA - H2-receptor antagonists
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist
D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists
D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents
Nizatidine is a potent and orally active histamine H2 receptor antagonist, can be used for the research of stomach?and?intestines ulcers. Nizatidine works by decreasing the secretion of gastric?acid the stomach makes and prevent ulcers from coming back after they have healed in animal models[1].

同义名列表

8 个代谢物同义名

dimethyl[(4-{[(2-{[(E)-1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}-1,3-thiazol-2-yl)methyl]amine; N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-n-methyl-2-nitro-1,1-ethenediamine; UNII-P41PML4GHR; Nizatidine; Acinon; Nizax; Axid; Nizatidine



数据库引用编号

20 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 4 ALB, CYP2C19, PTGS2, SLC9A1
Peripheral membrane protein 2 ACHE, PTGS2
Endoplasmic reticulum membrane 2 CYP2C19, PTGS2
Mitochondrion membrane 1 ABCG2
Nucleus 2 ACHE, ALB
cytosol 4 ALB, GPT, LEP, SST
dendrite 1 HRH2
mitochondrial membrane 1 ABCG2
centrosome 1 ALB
nucleoplasm 3 ABCG2, ATP2B1, SLC9A1
Cell membrane 5 ABCG2, ACHE, ATP2B1, HRH2, SLC9A1
lamellipodium 1 SLC9A1
Multi-pass membrane protein 5 ABCG2, ATP2B1, ATP4A, HRH2, SLC9A1
Synapse 4 ACHE, ATP2B1, HRH2, TAC1
cell surface 2 ACHE, SLC9A1
glutamatergic synapse 2 ATP2B1, GHRL
Golgi apparatus 2 ACHE, ALB
Golgi membrane 1 INS
lysosomal membrane 1 EGF
neuromuscular junction 1 ACHE
neuronal cell body 2 SST, TAC1
postsynapse 1 GHRL
presynaptic membrane 1 ATP2B1
plasma membrane 10 ABCG2, ACHE, ATP2B1, ATP4A, BCHE, CYP2C19, EGF, HRH2, IGHE, SLC9A1
synaptic vesicle membrane 1 ATP2B1
Membrane 6 ABCG2, ACHE, ATP2B1, ATP4A, EGF, SLC9A1
apical plasma membrane 3 ABCG2, ATP4A, SLC9A1
axon 2 GHRL, TAC1
basolateral plasma membrane 2 ATP2B1, SLC9A1
caveola 1 PTGS2
extracellular exosome 5 ALB, ATP2B1, EGF, GPT, SLC9A1
endoplasmic reticulum 2 ALB, PTGS2
extracellular space 12 ACHE, ALB, ATP4A, BCHE, EGF, GHRL, IGHE, IL10, INS, LEP, SST, TAC1
perinuclear region of cytoplasm 2 ACHE, SLC9A1
Schaffer collateral - CA1 synapse 1 GHRL
intercalated disc 1 SLC9A1
mitochondrion 1 SLC9A1
protein-containing complex 2 ALB, PTGS2
intracellular membrane-bounded organelle 2 ATP2B1, CYP2C19
Microsome membrane 1 PTGS2
Single-pass type I membrane protein 1 IGHE
Secreted 8 ACHE, ALB, BCHE, GHRL, IL10, INS, LEP, SST
extracellular region 11 ACHE, ALB, BCHE, EGF, GHRL, IGHE, IL10, INS, LEP, SST, TAC1
Extracellular side 1 ACHE
anchoring junction 1 ALB
Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane 1 ATP2B1
T-tubule 1 SLC9A1
neuronal dense core vesicle lumen 1 GHRL
Apical cell membrane 2 ABCG2, ATP4A
Membrane raft 2 ABCG2, SLC9A1
focal adhesion 1 SLC9A1
GABA-ergic synapse 1 SST
basement membrane 1 ACHE
lateral plasma membrane 1 ATP2B1
Nucleus inner membrane 1 PTGS2
Nucleus outer membrane 1 PTGS2
nuclear inner membrane 1 PTGS2
nuclear outer membrane 1 PTGS2
neuron projection 1 PTGS2
ciliary basal body 1 ALB
IgE immunoglobulin complex 1 IGHE
cell projection 1 ATP2B1
centriole 1 ALB
brush border membrane 1 ABCG2
spindle pole 1 ALB
blood microparticle 2 ALB, BCHE
Basolateral cell membrane 2 ATP2B1, SLC9A1
Lipid-anchor, GPI-anchor 1 ACHE
[Isoform 2]: Cell membrane 1 IGHE
endosome lumen 1 INS
Presynaptic cell membrane 1 ATP2B1
side of membrane 1 ACHE
secretory granule lumen 2 GHRL, INS
Golgi lumen 1 INS
endoplasmic reticulum lumen 5 ALB, BCHE, GHRL, INS, PTGS2
platelet alpha granule lumen 2 ALB, EGF
transport vesicle 1 INS
Endoplasmic reticulum-Golgi intermediate compartment membrane 1 INS
immunological synapse 1 ATP2B1
neuronal dense core vesicle 1 SST
nuclear envelope lumen 1 BCHE
clathrin-coated endocytic vesicle membrane 1 EGF
synaptic cleft 1 ACHE
external side of apical plasma membrane 1 ABCG2
[Isoform 3]: Cell membrane 1 IGHE
[Isoform 1]: Secreted 1 IGHE
IgE B cell receptor complex 1 IGHE
immunoglobulin complex, circulating 1 IGHE
photoreceptor ribbon synapse 1 ATP2B1
cation-transporting ATPase complex 1 SLC9A1
potassium:proton exchanging ATPase complex 1 ATP4A
[Isoform H]: Cell membrane 1 ACHE
ciliary transition fiber 1 ALB


文献列表

  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Yusra Rahman, Shumaila Afrin, Mustafa Alhaji Isa, Shahbaz Ahmed, Mohammad Tabish. Elucidating the molecular interaction of serum albumin with nizatidine and the role of β-cyclodextrin: multi-spectroscopic and computational approach. Journal of biomolecular structure & dynamics. 2020 Mar; 38(5):1375-1387. doi: 10.1080/07391102.2019.1604265. [PMID: 30955446]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • Rania El-Shaheny, Mohamed Radwan, Koji Yamada, Mahmoud El-Maghrabey. Estimation of nizatidine gastric nitrosatability and product toxicity via an integrated approach combining HILIC, in silico toxicology, and molecular docking. Journal of food and drug analysis. 2019 10; 27(4):915-925. doi: 10.1016/j.jfda.2019.08.001. [PMID: 31590763]
  • Kari M Morrissey, Sophie L Stocker, Eugene C Chen, Richard A Castro, Claire M Brett, Kathleen M Giacomini. The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers. Clinical pharmacokinetics. 2016 Apr; 55(4):495-506. doi: 10.1007/s40262-015-0332-9. [PMID: 26507723]
  • Salwa R Elshaboury, Niveen A Mohamed, Sameh Ahmed, Shereen Farrag. An Efficient Ion-Pair Liquid Chromatographic Method for the Determination of Some H2 Receptor Antagonists. Journal of chromatographic science. 2016 Mar; 54(3):419-28. doi: 10.1093/chromsci/bmv159. [PMID: 26538490]
  • Zhenwei Qin, Qiuli Fu, Lifang Zhang, Houfa Yin, Xiuming Jin, Qiaomei Tang, Danni Lyu, Ke Yao. Proliferative Effects of Histamine on Primary Human Pterygium Fibroblasts. Mediators of inflammation. 2016; 2016(?):9862496. doi: 10.1155/2016/9862496. [PMID: 27872516]
  • Filip Zmuda, Gaurav Malviya, Adele Blair, Marie Boyd, Anthony J Chalmers, Andrew Sutherland, Sally L Pimlott. Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo. Journal of medicinal chemistry. 2015 Nov; 58(21):8683-93. doi: 10.1021/acs.jmedchem.5b01324. [PMID: 26469301]
  • De-Wei Shang, Zhan-Zhang Wang, Xiao-Jia Ni, Ming Zhang, Jin-Qing Hu, Chang Qiu, Yu-Guan Wen. Development and validation of a sensitive LC-MS/MS assay for the quantification of nizatidine in human plasma and urine and its application to pharmacokinetic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2015 Aug; 998-999(?):80-7. doi: 10.1016/j.jchromb.2015.06.026. [PMID: 26197435]
  • Mahmut B Çakar, Sevgi T Ulu. HPLC fluorescence method for the determination of nizatidine in human plasma and its application to pharmacokinetic study. Luminescence : the journal of biological and chemical luminescence. 2014 Jun; 29(4):357-61. doi: 10.1002/bio.2552. [PMID: 23836529]
  • Naoto Takahashi, Masatomo Miura, Takenori Niioka, Kenichi Sawada. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer chemotherapy and pharmacology. 2012 Apr; 69(4):999-1004. doi: 10.1007/s00280-011-1797-3. [PMID: 22147077]
  • Yin-Xia Chang, Yue-Qin Qiu, Li-Ming Du, Chang-Feng Li, Min Guo. Determination of ranitidine, nizatidine, and cimetidine by a sensitive fluorescent probe. The Analyst. 2011 Oct; 136(20):4168-73. doi: 10.1039/c1an15078b. [PMID: 21858296]
  • Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance. Journal of medicinal chemistry. 2009 Aug; 52(15):4844-52. doi: 10.1021/jm900403j. [PMID: 19445515]
  • Shailendra Kapoor. Sjogren's syndrome: promising, new treatment options besides nizatidine. Modern rheumatology. 2009; 19(1):100-1. doi: 10.1007/s10165-008-0124-2. [PMID: 18841440]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • Diane A I Ashiru, Rajesh Patel, Abdul W Basit. Simple and universal HPLC-UV method to determine cimetidine, ranitidine, famotidine and nizatidine in urine: application to the analysis of ranitidine and its metabolites in human volunteers. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2007 Dec; 860(2):235-40. doi: 10.1016/j.jchromb.2007.10.029. [PMID: 18006395]
  • Sheila Seleri Marques Assunção, Sandra Inês Ruschel, Lucena de Cássia Rodrigues Rosa, João Alberto O Campos, Mercedes Jurema O Alves, Oswaldo Luis Bracco, Mauricio Silva de Lima. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2006 Dec; 28(4):270-6. doi: . [PMID: 17242805]
  • Ahmed Yusuf, Saleh Al Dgither, Muhammad M Hammami. Validation of a new high-performance liquid chromatography assay for nizatidine. Therapeutic drug monitoring. 2006 Apr; 28(2):232-6. doi: 10.1097/01.ftd.0000189902.08684.90. [PMID: 16628136]
  • Masato Sasaki, Toshiaki Sudoh, Akio Fujimura. Pharmacokinetics of ranitidine and nizatidine in very elderly patients. American journal of therapeutics. 2005 May; 12(3):223-5. doi: NULL. [PMID: 15891265]
  • Marilyn Lockyer, Saleh Al-Dgither, Eman Al-Gaai, Ahmed Yousuf, Muhammad M Hammami. Bioequivalence of two oral formulations of nizatidine capsules in healthy male volunteers. Biopharmaceutics & drug disposition. 2005 Apr; 26(3):117-20. doi: 10.1002/bdd.438. [PMID: 15723428]
  • Takako Nakano, Takashi Kuroiwa, Yuki Tsumita, Yoriaki Kaneko, Keiju Hiromura, Kazue Ueki, Yoshihisa Nojima. Aplastic anemia associated with initiation of nizatidine therapy in a hemodialysis patient. Clinical and experimental nephrology. 2004 Jun; 8(2):160-2. doi: 10.1007/s10157-003-0274-7. [PMID: 15235935]
  • Susan M Abdel-Rahman, Franklin K Johnson, James D Connor, Annamaria Staiano, Christophe Dupont, Vasundhara Tolia, Harland Winter, Ginette Gauthier-Dubois, Gregory L Kearns. Developmental pharmacokinetics and pharmacodynamics of nizatidine. Journal of pediatric gastroenterology and nutrition. 2004 Apr; 38(4):442-51. doi: 10.1097/00005176-200404000-00015. [PMID: 15085026]
  • Franco Lombardo, R Scott Obach, Marina Y Shalaeva, Feng Gao. Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Journal of medicinal chemistry. 2004 Feb; 47(5):1242-50. doi: 10.1021/jm030408h. [PMID: 14971904]
  • Murad Atmaca, Murat Kuloglu, Ertan Tezcan, Bilal Ustundag, Nulufer Kilic. Nizatidine for the treatment of patients with quetiapine-induced weight gain. Human psychopharmacology. 2004 Jan; 19(1):37-40. doi: 10.1002/hup.477. [PMID: 14716710]
  • Murad Atmaca, Murat Kuloglu, Ertan Tezcan, Bilal Ustundag. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Human psychopharmacology. 2003 Aug; 18(6):457-61. doi: 10.1002/hup.514. [PMID: 12923824]
  • Susan M Abdel-Rahman, Franklin K Johnson, Ginette Gauthier-Dubois, Irving E Weston, Gregory L Kearns. The bioequivalence of nizatidine (Axid) in two extemporaneously and one commercially prepared oral liquid formulations compared with capsule. Journal of clinical pharmacology. 2003 Feb; 43(2):148-53. doi: 10.1177/0091270002239823. [PMID: 12616667]
  • Kazunari Murakami, Ryugo Sato, Tadayoshi Okimoto, Koichiro Watanabe, Masaru Nasu, Toshio Fujioka, Masaaki Kodama, Jiro Kagawa. Influence of anti-ulcer drugs used in Japan on the result of (13)C-urea breath test for the diagnosis of Helicobacter pylori infection. Journal of gastroenterology. 2003; 38(10):937-41. doi: 10.1007/s00535-003-1176-x. [PMID: 14614600]
  • Robert A Blum, Alan J Braverman, Patricia Rice, Franklin K Johnson. Pharmacokinetics and pharmacodynamics of a novel nizatidine controlled-release formulation in healthy subjects. Journal of clinical pharmacology. 2003 Jan; 43(1):74-83. doi: 10.1177/0091270002239709. [PMID: 12520631]
  • Hiroki Itoh, Takafumi Naito, Masaharu Takeyama. Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide. The Journal of pharmacy and pharmacology. 2002 Nov; 54(11):1559-63. doi: 10.1211/002235702117. [PMID: 12495560]
  • Gail S Itokazu, James H Fischer, Prasarn Manitpisitkul, Radhika Hariharan, Larry H Danziger. Lack of effect of nizatidine-induced elevation of gastric pH on the oral bioavailability of dapsone in healthy volunteers. Pharmacotherapy. 2002 Nov; 22(11):1420-5. doi: 10.1592/phco.22.16.1420.33698. [PMID: 12432968]
  • Susan M Abdel-Rahman, Franklin K Johnson, Neil Manowitz, Gregory B Holmes, Gregory L Kearns. Single-dose pharmacokinetics of nizatidine (Axid) in children. Journal of clinical pharmacology. 2002 Oct; 42(10):1089-96. doi: 10.1177/009127002401382687. [PMID: 12362922]
  • Franco Lombardo, R Scott Obach, Marina Y Shalaeva, Feng Gao. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. Journal of medicinal chemistry. 2002 Jun; 45(13):2867-76. doi: 10.1021/jm0200409. [PMID: 12061889]
  • Hiroki Itoh, Toshiaki Nagano, Masaharu Takeyama. Effect of nizatidine on paracetamol and its metabolites in human plasma. The Journal of pharmacy and pharmacology. 2002 Jun; 54(6):869-73. doi: 10.1211/0022357021779050. [PMID: 12079004]
  • S M Wu, Y H Ho, H L Wu, S H Chen, H S Ko. Head-column field-amplified sample stacking in capillary electrophoresis for the determination of cimetidine, famotidine, nizatidine, and ranitidine-HCl in plasma. Electrophoresis. 2001 Aug; 22(13):2717-22. doi: 10.1002/1522-2683(200108)22:13<2717::aid-elps2717>3.0.co;2-2. [PMID: 11545397]
  • A A Al-Majed, F Belal, A M Al-Obaid, A H Dawoud. The voltammetric behavior of nizatidine and its determination in biological fluids. Journal of pharmaceutical and biomedical analysis. 1999 Nov; 21(2):319-26. doi: 10.1016/s0731-7085(99)00129-6. [PMID: 10703986]
  • G Gentilini, B R Curtis, R H Aster. An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies. Blood. 1998 Oct; 92(7):2359-65. doi: . [PMID: 9746775]
  • D S Weinberg, D Burnham, J A Berlin. Effect of histamine-2 receptor antagonists on blood alcohol levels: a meta-analysis. Journal of general internal medicine. 1998 Sep; 13(9):594-9. doi: 10.1046/j.1525-1497.1998.00181.x. [PMID: 9754514]
  • S Takedomi, H Matsuo, K Yamano, K Yamamoto, T Iga, Y Sawada. Quantitative prediction of the interaction of midazolam and histamine H2 receptor antagonists in rats. Drug metabolism and disposition: the biological fate of chemicals. 1998 Apr; 26(4):318-23. doi: NULL. [PMID: 9531518]
  • A B Thomson, V Mahachai, R J Bailey, P Kirdeikis, L Zuk, B Marriage, I Simpson, F Jamali. Twice daily nizatidine or ranitidine is superior to once daily dosing in elevating 24 h intragastric pH in patients with duodenal ulcer disease. Journal of gastroenterology and hepatology. 1996 Dec; 11(12):1171-6. doi: 10.1111/j.1440-1746.1996.tb01847.x. [PMID: 9034938]
  • J G Hatlebakk, A Berstad. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clinical pharmacokinetics. 1996 Nov; 31(5):386-406. doi: 10.2165/00003088-199631050-00005. [PMID: 9118586]
  • F Jamali, A B Thomson, P Kirdeikis, M Tavernini, L Zuk, B Marriage, I Simpson, V Mahachai. Diurnal variation in the pharmacokinetics of nizatidine in healthy volunteers and in patients with peptic ulcer disease. Journal of clinical pharmacology. 1995 Nov; 35(11):1071-5. doi: 10.1002/j.1552-4604.1995.tb04029.x. [PMID: 8626880]
  • A Thompson, P Kirdeikis, F Jamali, M Tavernini, L Zuk, B Marriage, I Simpson, V Mahachai. Effect of nizatidine and ranitidine on 24 hour intragastric pH, pepsin, prostaglandin E2 and serum gastrin concentrations in healthy volunteers. Journal of gastroenterology and hepatology. 1995 Sep; 10(5):546-54. doi: 10.1111/j.1440-1746.1995.tb01345.x. [PMID: 8963030]
  • R Gugler. H2-antagonists and alcohol. Do they interact?. Drug safety. 1994 Apr; 10(4):271-80. doi: 10.2165/00002018-199410040-00001. [PMID: 7912509]
  • T J Sullivan, J H Reese, L Jauregui, K Miller, L Levine, K A Bachmann. Short report: a comparative study of the interaction between antacid and H2-receptor antagonists. Alimentary pharmacology & therapeutics. 1994 Feb; 8(1):123-6. doi: 10.1111/j.1365-2036.1994.tb00168.x. [PMID: 7910488]
  • L R Levine, M L Cloud, N H Enas. Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs. Archives of internal medicine. 1993 Nov; 153(21):2449-54. doi: . [PMID: 8215749]
  • K A Bachmann, T J Sullivan, L Jauregui, J H Reese, K Miller, L Levine. Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity. British journal of clinical pharmacology. 1993 Oct; 36(4):380-2. doi: 10.1111/j.1365-2125.1993.tb00382.x. [PMID: 12959321]
  • J M van Zyl, A Kriegler, B J van der Walt. Anti-oxidant properties of H2-receptor antagonists. Effects on myeloperoxidase-catalysed reactions and hydroxyl radical generation in a ferrous-hydrogen peroxide system. Biochemical pharmacology. 1993 Jun; 45(12):2389-97. doi: 10.1016/0006-2952(93)90218-l. [PMID: 8101078]
  • S Saima, H Echizen, K Yoshimoto, T Ishizaki. Hemofiltrability of histamine H2-receptor antagonist, nizatidine, and its metabolites in patients with renal failure. Journal of clinical pharmacology. 1993 Apr; 33(4):324-9. doi: 10.1002/j.1552-4604.1993.tb04664.x. [PMID: 8473546]
  • J P Raufman, V Notar-Francesco, R D Raffaniello, E W Straus. Histamine-2 receptor antagonists do not alter serum ethanol levels in fed, nonalcoholic men. Annals of internal medicine. 1993 Apr; 118(7):488-94. doi: 10.7326/0003-4819-118-7-199304010-00002. [PMID: 8095127]
  • P Duroux, C Emde, P Bauerfeind, J Biollaz, D Armstrong, A L Blum. Early evening nizatidine intake with a meal optimizes the antisecretory effect. Alimentary pharmacology & therapeutics. 1993 Feb; 7(1):47-54. doi: 10.1111/j.1365-2036.1993.tb00068.x. [PMID: 8439637]
  • P A Milligan, P E McGill, C W Howden, A W Kelman, B Whiting. The consequences of H2 receptor antagonist--piroxicam coadministration in patients with joint disorders. European journal of clinical pharmacology. 1993; 45(6):507-12. doi: 10.1007/bf00315306. [PMID: 7908879]
  • K Bachmann, T J Sullivan, L S Mauro, M Martin, L Jauregui, L Levine. Comparative investigation of the influence of nizatidine, ranitidine, and cimetidine on the steady-state pharmacokinetics of theophylline in COPD patients. Journal of clinical pharmacology. 1992 May; 32(5):476-82. doi: 10.1002/j.1552-4604.1992.tb03865.x. [PMID: 1587967]
  • J Caballería, E Baraona, R Deulofeu, R Hernández-Muñoz, J Rodés, C S Lieber. Effects of H2-receptor antagonists on gastric alcohol dehydrogenase activity. Digestive diseases and sciences. 1991 Dec; 36(12):1673-9. doi: 10.1007/bf01296608. [PMID: 1684149]
  • C U Nwokolo, J T Smith, A M Sawyerr, R E Pounder. Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade. Gut. 1991 Dec; 32(12):1455-60. doi: 10.1136/gut.32.12.1455. [PMID: 1685465]
  • M T Popat, O J Dyar, C E Blogg. Comparison of the effects of oral nizatidine and ranitidine on gastric volume and pH in patients undergoing gynaecological laparoscopy. Anaesthesia. 1991 Oct; 46(10):816-9. doi: 10.1111/j.1365-2044.1991.tb09591.x. [PMID: 1683179]
  • H Sano, H Sato, S Furuta, M Mogi, Y Matsuki, M Motogi. Pharmacokinetics of nizatidine in dogs and rats. Xenobiotica; the fate of foreign compounds in biological systems. 1991 Oct; 21(10):1257-64. doi: 10.3109/00498259109043200. [PMID: 1796603]
  • H Sano, Y Mera, K Arai, M Suzuki, H Sato, K Matsuda. Localization of 14C-nizatidine in the gastric wall of rats. Arzneimittel-Forschung. 1991 Sep; 41(9):958-61. doi: . [PMID: 1796925]
  • Y Yamaji, T Omata, T Abe, A Yoshida, S Ueki, H Aita, H Morita, K Chaki, Y Segawa, T Kurimoto. Effects of successive doses of nizatidine, cimetidine and ranitidine on serum gastrin level and gastric acid secretion. Arzneimittel-Forschung. 1991 Sep; 41(9):954-7. doi: . [PMID: 1796924]
  • G M Fullarton, A M Macdonald, K E McColl. Rebound hypersecretion after H2-antagonist withdrawal--a comparative study with nizatidine, ranitidine and famotidine. Alimentary pharmacology & therapeutics. 1991 Aug; 5(4):391-8. doi: 10.1111/j.1365-2036.1991.tb00042.x. [PMID: 1685675]
  • J Hatton, S G Holstad, A D Rosenbloom, T Westrich, J Hirsch. Stability of nizatidine in total nutrient admixtures. American journal of hospital pharmacy. 1991 Jul; 48(7):1507-10. doi: . [PMID: 1679293]
  • P Villani, M B Regazzi, M Pecorini, M Tizzoni, D Savio. The effect of aging on the pharmacokinetics of nizatidine. European journal of drug metabolism and pharmacokinetics. 1991; Spec No 3(?):205-10. doi: NULL. [PMID: 1820880]
  • A Tracqui, P Kintz, P Mangin. Determination of nizatidine and two of its main metabolites in human serum using high-performance liquid chromatography. Journal of chromatography. 1990 Aug; 529(2):369-76. doi: 10.1016/s0378-4347(00)83843-8. [PMID: 1977754]
  • B D Obermeyer, R F Bergstrom, J T Callaghan, M P Knadler, A Golichowski, A Rubin. Secretion of nizatidine into human breast milk after single and multiple doses. Clinical pharmacology and therapeutics. 1990 Jun; 47(6):724-30. doi: 10.1038/clpt.1990.100. [PMID: 1972674]
  • D W Schneck, J T Callaghan, R F Bergstrom, B D Obermeyer, W W Offen. Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion. Clinical pharmacology and therapeutics. 1990 Apr; 47(4):499-503. doi: 10.1038/clpt.1990.63. [PMID: 2109665]
  • G Carlucci. High-performance liquid chromatographic assay for nizatidine, a new H2 blocker, in human plasma and urine using disposable solid-phase extraction columns. Journal of chromatography. 1990 Feb; 525(2):490-4. doi: 10.1016/s0378-4347(00)83429-5. [PMID: 1970345]
  • B L Neubauer, R L Goode, K L Best, K S Hirsch, T M Lin, R P Pioch, K S Probst, F C Tinsley, C J Shaar. Endocrine effects of a new histamine H2-receptor antagonist, nizatidine (LY139037), in the male rat. Toxicology and applied pharmacology. 1990 Feb; 102(2):219-32. doi: 10.1016/0041-008x(90)90022-m. [PMID: 1967857]
  • V Filingeri, R Rosati, R Giacomelli, G Famularo, A Iacona, V Cervelli, E Davoli, G Tonietti, C U Casciani. Drug interaction between cyclosporin A and nizatidine in Sprague-Dawley rats. Drugs under experimental and clinical research. 1990; 16(9):475-9. doi: NULL. [PMID: 1983111]
  • C U Nwokolo, J T Smith, C Gavey, A Sawyerr, R E Pounder. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Alimentary pharmacology & therapeutics. 1990; 4 Suppl 1(?):29-45. doi: NULL. [PMID: 1983345]
  • P N Maton, J D Gardner, R T Jensen. Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology clinics of North America. 1989 Dec; 18(4):847-63. doi: NULL. [PMID: 2575602]
  • K S Probst, G L Higdon, L F Fisher, J P McGrath, E R Adams, J L Emmerson. Preclinical toxicology studies with nizatidine, a new H2-receptor antagonist: acute, subchronic, and chronic toxicity evaluations. Fundamental and applied toxicology : official journal of the Society of Toxicology. 1989 Nov; 13(4):778-92. doi: 10.1016/0272-0590(89)90333-3. [PMID: 2576009]
  • L Danziger, K M Furmaga, K A Rodvold, C T Bombeck, J H Fischer. Nizatidine suppression of basal gastric acid output: a comparison of two intravenous dosage regimens. Journal of clinical pharmacology. 1989 Oct; 29(10):946-52. doi: 10.1002/j.1552-4604.1989.tb03259.x. [PMID: 2574190]
  • G M Fullarton, G McLauchlan, A Macdonald, G P Crean, K E McColl. Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist. Gut. 1989 Apr; 30(4):449-54. doi: 10.1136/gut.30.4.449. [PMID: 2565860]
  • J P Desager, C Harvengt. Oral bioavailability of nizatidine and ranitidine concurrently administered with antacid. The Journal of international medical research. 1989 Jan; 17(1):62-7. doi: 10.1177/030006058901700109. [PMID: 2565267]
  • A Cournot, I Berlin, J C Sallord, E Singlas. Lack of interaction between nizatidine and warfarin during chronic administration. Journal of clinical pharmacology. 1988 Dec; 28(12):1120-2. doi: 10.1002/j.1552-4604.1988.tb05727.x. [PMID: 2907521]
  • S Lanzon-Miller, R E Pounder, N A Chronos, F Raymond, M R Hamilton, D Dalgleish. Twenty four hour intragastric acidity and plasma gastrin concentration in healthy volunteers taking nizatidine 150 mg, nizatidine 300 mg, ranitidine 300 mg, or placebo at 21:00 h. Gut. 1988 Oct; 29(10):1364-9. doi: 10.1136/gut.29.10.1364. [PMID: 2904394]
  • G R Aronoff, R F Bergstrom, R J Bopp, R S Sloan, J T Callaghan. Nizatidine disposition in subjects with normal and impaired renal function. Clinical pharmacology and therapeutics. 1988 Jun; 43(6):688-95. doi: 10.1038/clpt.1988.97. [PMID: 2897890]
  • D R Forsyth, K S Jayasinghe, C J Roberts. Do nizatidine and cimetidine interact with ibuprofen?. European journal of clinical pharmacology. 1988; 35(1):85-8. doi: 10.1007/bf00555513. [PMID: 2905991]
  • U Klotz, W Gottlieb, P P Keohane, H G Dammann. Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. Journal of clinical pharmacology. 1987 Mar; 27(3):210-2. doi: 10.1002/j.1552-4604.1987.tb02186.x. [PMID: 2890666]
  • D M Morton. Pharmacology and toxicology of nizatidine. Scandinavian journal of gastroenterology. Supplement. 1987; 136(?):1-8. doi: 10.3109/00365528709094479. [PMID: 2892249]
  • J T Callaghan, R F Bergstrom, A Rubin, S Chernish, R Crabtree, M P Knadler, B Obermeyer, W W Offen, D W Schneck, G Aronoff. A pharmacokinetic profile of nizatidine in man. Scandinavian journal of gastroenterology. Supplement. 1987; 136(?):9-17. doi: 10.3109/00365528709094480. [PMID: 2892261]
  • T O Kovacs, G M Van Deventer, V Maxwell, B Sytnik, J H Walsh. The effect of an oral evening dose of nizatidine on nocturnal and peptone-stimulated gastric acid and gastrin secretion. Scandinavian journal of gastroenterology. Supplement. 1987; 136(?):41-6. doi: 10.3109/00365528709094485. [PMID: 2892254]
  • U Klotz. Lack of effect of nizatidine on drug metabolism. Scandinavian journal of gastroenterology. Supplement. 1987; 136(?):18-23. doi: 10.3109/00365528709094481. [PMID: 2892251]
  • M L Cloud. Safety of nizatidine in clinical trials conducted in the USA and Europe. Scandinavian journal of gastroenterology. Supplement. 1987; 136(?):29-36. doi: 10.3109/00365528709094483. [PMID: 2892253]
  • H Levendoglu, B Mehta, C Wait, G Reddy, C Hatcher. Nizatidine: a new histamine receptor blocker in the treatment of active duodenal ulcers. The American journal of gastroenterology. 1986 Dec; 81(12):1167-70. doi: . [PMID: 2878607]
  • M P Knadler, R F Bergstrom, J T Callaghan, A Rubin. Nizatidine, an H2-blocker. Its metabolism and disposition in man. Drug metabolism and disposition: the biological fate of chemicals. 1986 Mar; 14(2):175-82. doi: NULL. [PMID: 2870891]
  • C G Meredith, K V Speeg, S Schenker. Nizatidine, a new histamine H2-receptor antagonist, and hepatic oxidative drug metabolism in the rat: a comparison with structurally related compounds. Toxicology and applied pharmacology. 1985 Feb; 77(2):315-24. doi: 10.1016/0041-008x(85)90331-x. [PMID: 2858133]
  • J T Callaghan, R F Bergstrom, B D Obermeyer, E P King, W W Offen. Intravenous nizatidine kinetics and acid suppression. Clinical pharmacology and therapeutics. 1985 Feb; 37(2):162-5. doi: 10.1038/clpt.1985.29. [PMID: 2857117]